Posted by Michael Wonder on 14 Jul 2021
FDA grants Alkeus Pharmaceuticals breakthrough therapy designation for ALK-001 (C20-D3-vitamin A) for the treatment of Stargardt disease
14 July 2021 - Only drug to receive breakthrough therapy designation for Stargardt disease.
Alkeus Pharmaceuticals today announced that the U.S. FDA has granted breakthrough therapy designation to ALK-001 for the treatment of Stargardt disease.
